CFCassio Mendes Fontes

Cassio Mendes Fontes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cassio Mendes Fontes has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Plasmonically Enhanced Microarray Immunoassay for High‐Sensitivity Monitoring of Heart Failure

    by Daria Semeniak, Deniz Acil, Jason Liu, Daniela F. Cruz, Cassio M. Fontes, Chengyang Li, Brooke E. Silverstein, G. Michael Felker, Angus M. Hucknall, Maiken H. Mikkelsen, et al.

    Point‑of‑care testing (POCT) demands diagnostic platforms that pair high analytical sensitivity with compact, low‑cost readout hardware, yet fluorescence‑based immunoassays face a fundamental tradeoff between detector cost and detection performance. Plasmonic nanocavities—such as metal–dielectric–metal nanopatch antennas—offer a powerful signal‑amplification strategy by dramatically enhancing fluorophore emission, enabling sensitive fluorescence detection with inexpensive optics. Here, we introduce a plasmonically enhanced fluorescence microarray immunoassay that integrates nanopatch antennas for high‑sensitivity, low‑cost quantification of key heart‑failure biomarkers, NT‑proBNP, NGAL, and galectin‑3, using a custom smartphone‑based detector. The nanopatch antennas yield up to 485‑fold fluorescence enhancement enabling quantitative and multiplexed detection with limits of detection of 0.055, 3.932, and 0.864 ng/mL, respectively. Analysis of NT‑proBNP–positive human samples shows strong correlation with clinically validated assays, demonstrating the potential of this plasmonically enhanced platform to deliver high‑performance heart‑failure biomarker monitoring at low cost in resource‑limited and point‑of‑care settings.

  • Open Access

    Controlling Release Kinetics of an Adjuvant from a Depot Improves the Efficacy of Local Immunotherapy in Metastatic Cancer

    by Joshua J. Milligan, Rachel L. Strader, Arunangshu Chakrabarty, Max Ney, Parul Sirohi, Jonathan C. Su, Anastasia K. Varanko, Yulia Shmidov, Kalina Tsolova, Cassio Mendes Fontes, et al.

    Biomaterials can improve cancer immunotherapies by controlling their release and thereby optimizing their time‐dependent engagement of the immune system. In this study, an approach is described to control the release of a potent immunostimulant—CpG oligodeoxynucleotide—from a genetically‐encoded elastin‐like polypeptide (ELP) depot. A CpG‐binding ELP containing an oligolysine domain (ELP‐Lys 12 ) is synthesized that electrostatically complexes CpG and formulate it with an excipient ELP. The ELP‐CpG complex retains the thermally responsive phase behavior of the parent ELP, transitioning into a viscous depot at body temperature. Stepwise addition of excipient ELP predictably changes ELP‐CpG transition temperature, depot dissolution kinetics, and retention of CpG within the depot. Mixtures of ELP‐Lys 12 , excipient ELP, and CpG undergo microphase separation, forming a porous, sponge‐like depot that contains tunable amounts of soluble CpG in the pores. In vivo, the modified formulations exhibit varying degrees of CpG retention over multiple weeks following a single intratumoral injection. Finally, by modifying the release kinetics of CpG, optimized ELP‐CpG achieves greater reduction of metastatic disease in a murine metastatic breast cancer model than soluble CpG. These results demonstrate that ELPs can be used to precisely tune the release kinetics of immunotherapies for better outcomes in the treatment of metastatic cancer.


  • Top Cited Papers

    Synthetic biomolecular condensates enhance translation from a target mRNA in living cells

    by Daniel Mark Shapiro, Sonal Deshpande, Seyed Ali Eghtesadi, Miranda Zhong, Cassio Mendes Fontes, David Fiflis, Dahlia Rohm, Junseon Min, Taranpreet Kaur, Joanna Peng, et al.

    Biomolecular condensates composed of proteins and RNA are one approach by which cells regulate post-transcriptional gene expression. Their formation typically involves the phase separation of intrinsically disordered proteins with a target mRNA, sequestering the mRNA into a liquid condensate. This sequestration regulates gene expression by modulating translation or facilitating RNA processing. Here we engineer synthetic condensates using a fusion of an RNA-binding protein, the human Pumilio2 homology domain (Pum2), and a synthetic intrinsically disordered protein, an elastin-like polypeptide (ELP), that can bind and sequester a target mRNA transcript. In protocells, sequestration of a target mRNA largely limits its translation. Conversely, in Escherichia coli, sequestration of the same target mRNA increases its translation. We characterize the Pum2–ELP condensate system using microscopy, biophysical and biochemical assays, and RNA sequencing. This approach enables the modulation of cell function via the formation of synthetic biomolecular condensates that regulate the expression of a target protein.


  • Environmentally Resilient Microfluidic Point-of-Care Immunoassay Enables Rapid Diagnosis of Talaromycosis

    by David S. Kinnamon, Jacob T. Heggestad, Jason Liu, Thu Nguyen, Vo Ly, Angus M. Hucknall, Cassio M. Fontes, Rhett J. Britton, Jian-Piao Cai, Jasper Fuk-Woo Chan, et al.

    Point-of-care tests (POCTs) are increasingly being used in field settings, particularly outdoors. The performance of current POCTs─most commonly the lateral flow immunoassay─can be adversely affected by ambient temperature and humidity. We developed a self-contained immunoassay platform─the D4 POCT─that can be conducted at the POC by integrating all reagents in a capillary-driven passive microfluidic cassette that minimizes user intervention. The assay can be imaged and analyzed on a portable fluorescence reader─the D4Scope─and provide quantitative outputs. Here, we systematically investigated the resilience of our D4 POCT to varied temperature and humidity and to physiologically diverse human whole blood samples that span a wide range of physiological hematocrit (30-65%). For all conditions, we showed that the platform maintained high sensitivity (0.05-0.41 ng/mL limits of detection). The platform also demonstrated good accuracy in reporting true analyte concentration across environmental extremes when compared to the manually operated format of the same test to detect a model analyte─ovalbumin. Additionally, we engineered an improved version of the microfluidic cassette that improved the ease-of-use of the device and shortened the time-to-result. We implemented this new cassette to create a rapid diagnostic test to detect talaromycosis infection in patients with advanced HIV disease at the POC, demonstrating comparable sensitivity and specificity to the laboratory test for the disease.


  • COVID-19 Diagnosis and SARS-CoV-2 Strain Identification by a Rapid, Multiplexed, Point-of-Care Antibody Microarray

    by Jacob T. Heggestad, Rhett J. Britton, David S. Kinnamon, Jason Liu, Jack G. Anderson, Daniel Y. Joh, Zachary Quinn, Cassio M. Fontes, Angus M. Hucknall, Robert Parks, et al.

    Antigen tests to detect SARS-CoV-2 have emerged as a promising rapid diagnostic method for COVID-19, but they are unable to differentiate between variants of concern (VOCs). Here, we report a rapid point-of-care test (POC-T), termed CoVariant-SPOT, that uses a set of antibodies that are either tolerant or intolerant to spike protein mutations to identify the likely SARS-CoV-2 strain concurrent with COVID-19 diagnosis using antibodies targeting the nucleocapsid protein. All reagents are incorporated into a portable, multiplexed, and sensitive diagnostic platform built upon a nonfouling polymer brush. To validate CoVariant-SPOT, we tested recombinant SARS-CoV-2 proteins, inactivated viruses, and nasopharyngeal swab samples from COVID-19 positive and negative individuals and showed that CoVariant-SPOT can readily distinguish between two VOCs: Delta and Omicron. We believe that CoVariant-SPOT can serve as a valuable adjunct to next-generation sequencing to rapidly identify variants using a scalable and deployable POC-T, thereby enhancing community surveillance efforts worldwide and informing treatment selection.


  • Smartphone Enabled Point-of-Care Detection of Serum Biomarkers

    by Jacob T. Heggestad, David S. Kinnamon, Jason Liu, Daniel Y. Joh, Cassio M. Fontes, Qingshan Wei, Aydogan Ozcan, Angus M. Hucknall, Ashutosh Chilkoti

    Sandwich immunoassays are the gold standard for detection of protein analytes. Here, we describe an ultrasensitive point-of-care sandwich immunoassay platform for the detection of biomarkers directly from blood or serum using a custom-built smartphone detector. Testing undiluted blood or serum is challenging due to the complexity of the matrix. Proteins nonspecifically adsorb to and cells often adhere to the assay surface, which can drastically impact the analytical sensitivity of the assay. To address this problem, our assay is built upon a “nonfouling” polymer brush “grafted from” a glass slide, which eliminates nearly all nonspecific binding and therefore increases the signal-to-noise ratio and greatly improves the analytical performance of the test. The two components required to perform a sandwich immunoassay are inkjet-printed directly onto the surface: (1) “stable” capture antibodies that remain entrapped in the brush even after exposure to a liquid sample and (2) fluorescently labeled “soluble” detection antibodies that dissolve upon exposure to a liquid sample. The polymer brush provides hydration to the antibodies, allowing them to remain stable and active over prolonged periods of time. When a liquid sample containing a biomarker of interest is dispensed onto the chip, the detection antibodies dissolve and diffuse to the stable capture spots forming a complex that sandwiches the analyte and that has a fluorescence intensity proportional to the concentration of the biomarker in solution, which can be measured using a custom-built smartphone detector. As multiple capture antibodies can be printed as discrete capture spots, the assay can be easily multiplexed without the need for multiple fluorophores. This chip and detector platform can be utilized for the point-of-care detection of low-abundance biomarkers directly from blood or serum in low-resource settings.


  • Open Access

    Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test

    by Jacob T. Heggestad, David S. Kinnamon, Lyra B. Olson, Jason Liu, Garrett Kelly, Simone A. Wall, Solomon Oshabaheebwa, Zachary Quinn, Cassio M. Fontes, Daniel Y. Joh, et al.

    A point-of-care, microfluidic platform detects antibodies against three SARS-CoV-2 antigens from blood in less than an hour.


  • Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR

    by Cassio M. Fontes, Barbara D. Lipes, Jason Liu, Krystle N. Agans, Aiwei Yan, Patricia Shi, Daniela F. Cruz, Garrett Kelly, Kelli M. Luginbuhl, Daniel Y. Joh, et al.

    An immunoassay that targets the nonstructural secreted glycoprotein decoy antigen of Ebola virus detects infection earlier than PCR.


  • Open Access

    Ultrabright Fluorescence Readout of an Inkjet-Printed Immunoassay Using Plasmonic Nanogap Cavities

    by Daniela F. Cruz, Cassio M. Fontes, Daria Semeniak, Jiani Huang, Angus Hucknall, Ashutosh Chilkoti, Maiken H. Mikkelsen

    Fluorescence-based microarrays are promising diagnostic tools due to their high throughput, small sample volume requirements, and multiplexing capabilities. However, their low fluorescence output has limited their implementation for in vitro diagnostics applications in point-of-care (POC) settings. Here, by integration of a sandwich immunoassay microarray within a plasmonic nanogap cavity, we demonstrate strongly enhanced fluorescence which is critical for readout by inexpensive POC detectors. The immunoassay consists of inkjet-printed antibodies on a polymer brush which is grown on a gold film. Colloidally synthesized silver nanocubes are placed on top and interact with the underlying gold film creating high local electromagnetic field enhancements. By varying the thickness of the brush from 5 to 20 nm, up to a 151-fold increase in fluorescence and 14-fold improvement in the limit-of-detection is observed for the cardiac biomarker B-type natriuretic peptide (BNP) compared to the unenhanced assay, paving the way for a new generation of POC clinical diagnostics.


  • Engineering the Surface Properties of a Zwitterionic Polymer Brush to Enable the Simple Fabrication of Inkjet-Printed Point-of-Care Immunoassays

    by Cassio M. Fontes, Rohan K. Achar, Daniel Youngjin Joh, Imran Ozer, Somnath Bhattacharjee, Angus Hucknall, Ashutosh Chilkoti

    Motivated by the lack of adventitious protein adsorption on zwitterionic polymer brushes that promise low noise and hence high analytical sensitivity for surface-based immunoassays, we explored their use as a substrate for immunoassay fabrication by inkjet printing of antibodies. We observed that a poly(sulfobetaine)methacrylate brush on glass is far too hydrophilic to enable non-covalent immobilization of antibodies by inkjet printing. To circumvent this limitation, we developed a series of hybrid zwitterionic-cationic surface coatings with tunable surface wettability that are suitable for inkjet printing of antibodies, but which also have low protein adsorption. We show that in a microarray format in which both capture and detection antibodies are discretely printed as spots on these hybrid brushes, a point-of-care sandwich immunoassay can be carried out with an analytical sensitivity and dynamic range that is similar to or better than the same assay fabricated on a PEG-like brush. We also show that the hybrid polymer brushes do not bind anti-PEG antibodies that are ubiquitous in human blood, which can be a problem with immunoassays fabricated on PEG-like coatings.